Autolus Therapeutics rises on FDA tag for cancer therapy

Autolus Therapeutics

25/04/2022 15:56

** Drug developer's shares  AUTL.O  rise 1.9% to $3.48
    ** U.S. FDA grants Regenerative Medicine Advanced Therapy
designation to co's lead gene therapy, Obe-cel, for treatment of
adult patients with a type of cancer of the blood and bone
marrow  urn:newsml:reuters.com:*:nGNX3Dfn4c
    ** FDA's RMAT designation helps speed up development and
approval of regenerative medicine products, including cell and
gene therapies
    ** Obe-cel is currently being tested in an ongoing mid-stage
study of adults with B-Acute Lymphocytic Leukemia
    ** Stock down ~33% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))